Maria Wlaschitz
Eva-Maria Wlaschitz, a development scientist at Boehringer Ingelheim in Vienna, Austria, speaks about the numerous growth opportunities.
Search
Liliana Montano
Liliana Montano works as a scientist within the Global Innovation and Alliance Management and talks about her journey at Boehringer Ingelheim.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Vetmedica, Inc. Opens New R&D Facility | Boehringer Ingelheim US
Find out more on the opening of Boehringer Ingelheim Vetmedica Inc's new research and development facility in Ames, Iowa.
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Respiratory
Respiratory
Mental Health disorders
Mental Health disorders
Submit Your Partnering Opportunity
Submit Your Partnering Opportunity
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
Investigating MDM2-p53 in cancer
Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Innovation in CNS Disease Research
Innovation in CNS Disease Research
Partnering Days
Partnering Days
Research Beyond Borders
Research Beyond Borders
Technologies
Technologies
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Cardio-Renal-Metabolic diseases
Cardio-Renal-Metabolic diseases
Talking drug discovery with our U.S. research site head, Carine Boustany
Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases